Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies

NCT03297424 is registered in ClinicalTrials.gov with Opna Bio LLC as lead sponsor.

NCT NCT03297424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03297424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies
Lead sponsor
Opna Bio LLC
Phase
Phase 1
Overall status
Completed
Start date
September 12, 2017
Completion date
June 7, 2021
Enrollment
49 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, diffuse large b cell lymphoma, follicular lymphoma, non-hodgkin lymphoma, ovarian clear cell carcinoma, small cell lung cancer, solid tumor, uveal melanoma